Agilent Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma
August 08 2018 - 3:00AM
Business Wire
PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify
Urothelial Carcinoma Patients for Treatment With KEYTRUDA®
(pembrolizumab)
Agilent Technologies Inc. (NYSE: A) today announced that its
PD-L1 IHC 22C3 pharmDx assay is now labeled for an updated use in
urothelial carcinoma in Europe.
Physicians in Europe can now use the assay as an aid to identify
urothelial carcinoma patients who are ineligible for cisplatin and
may respond to KEYTRUDA (pembrolizumab) as a first-line treatment
option. KEYTRUDA is a targeted anti-PD-1 immunotherapy manufactured
by Merck (known as MSD outside the United States and Canada). It is
a humanized monoclonal antibody that may increase the ability of
the body's immune system to help detect and fight tumor cells.
“We are pleased that PD-L1 IHC 22C3 pharmDx will help physicians
identify urothelial carcinoma patients for whom KEYTRUDA may be an
appropriate first-line treatment option. Being able to support the
use of immuno-oncology therapeutics by bringing their associated
diagnostics to market is truly encouraging,” said Sam Raha,
president of Agilent's Diagnostics and Genomics Group.
Agilent is a worldwide leader in partnering with pharmaceutical
companies to develop immunohistochemical-based diagnostics for
cancer therapy. Agilent developed PD-L1 IHC 22C3 pharmDx in
partnership with Merck. PD-L1 expression in urothelial carcinoma
tissues is interpreted using Combined Positive Score (CPS). PD-L1
IHC 22C3 pharmDx also helps physicians identify non-small cell lung
cancer (NSCLC) patients for treatment with KEYTRUDA. PD-L1
expression in NSCLC tissues is interpreted using Tumor Proportion
Score (TPS).
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.47 billion in fiscal 2017 and employs 14,200 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
our Newsroom.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180808005144/en/
Agilent TechnologiesVictoria Wadsworth-Hansen, +1
408-553-2005+45 2933 6980victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024